PAHC — Phibro Animal Health Corp
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $55.16
- 30-Day Move
- +35.9%
- Market Cap
- $2.3B
- Shares Outstanding
- 40,530,000
- P/E Ratio
- 25.01
- P/B Ratio
- 3.62
Analyst consensus: Sell · 9 analysts
Phibro Animal Health Corp
A read-only Alphactor snapshot forPhibro Animal Health Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$55.16
30-Day Move
+35.9%
Market Cap
$2.3B
Shares Outstanding
40,530,000
P/E Ratio
25.01
P/B Ratio
3.62
$55.16
+35.9%last 90 delayed daily bars
90D High
$60.08
90D Low
$36.14
Avg Volume
274,299
Gross margin is running at 32.6%, which gives a quick read on operating quality before you open the full model.
Net margin is 6.3%, useful for comparing PAHC against peers in Pharmaceuticals.
PAHC is up 35.9% over the last 30 trading days shown on this page.
Latest operating income is $110M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$48.96
Rule of 40
30.6%
Dark Pool Short %
77.3%
Latest Close
$55.16
30-Day Move
+35.9%
Market Cap
$2.3B
Shares Outstanding
40,530,000
P/E Ratio
25.01
P/B Ratio
3.62
ROE
16.9%
ROA
3.5%
Gross Margin
32.6%
Operating Margin
11.5%
Net Margin
6.3%
Debt / Equity
2.52
Current Ratio
2.76
Dividend Yield
86.5%
Latest Revenue
$1.3B
Revenue
$1.3B
Gross Profit
$400M
Operating Income
$110M
Net Income
$48M
Gross Margin
3256.0%
Net Margin
629.0%
Current Ratio
2.76
Debt / Equity
2.52
Fair Value
$48.96
Upside / Downside
-11.2%
Signal
Overvalued
Implied Growth
25.7%
DCF
$2.37
EPV
$1.70
EV/Rev
$142.80
Growth Assumption
11.2%
Discount Rate
9.9%
Terminal Growth
2.0%
Base FCF
$42M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
3.25
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
1.66x
Rule of 40
30.6%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $942M | $79M | $49M | $-5M |
| 2023-12-31 | $978M | $72M | $33M | $-38M |
| 2024-12-31 | $1.0B | $53M | $2M | $46M |
| 2025-12-31 | $1.3B | $110M | $48M | $42M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$22M
Buys
0
Sells
83
Buy Value
$0
Sell Value
$22M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-23 | BENDHEIM JACK | Sell | 421 | $54.56 |
| 2026-04-23 | BENDHEIM JACK | Sell | 6,619 | $54.07 |
| 2026-04-22 | BENDHEIM JACK | Sell | 7,040 | $54.29 |
| 2026-04-21 | BENDHEIM JACK | Sell | 5,415 | $56.17 |
| 2026-04-21 | BENDHEIM JACK | Sell | 1,625 | $55.35 |
| 2026-04-16 | BENDHEIM JACK | C | 100,000 | $0.00 |
| 2026-04-16 | BENDHEIM JACK | Sell | 1,850 | $54.88 |
| 2026-04-16 | BENDHEIM JACK | Sell | 5,190 | $54.56 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 1,244,469 | 0.06% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 639,226 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 494,110 | 0.02% | 2026-02-28 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 380,135 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 221,060 | 0.01% | 2025-12-31 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 204,800 | 0.01% | 2025-12-31 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 199,134 | 0.01% | 2026-01-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 198,373 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Vanguard Group
Filed 2025-11-07
$62M
-1.5%
BlackRock
Filed 2024-08-13
$59M
--
FMR LLC (Fidelity)
Filed 2026-02-17
$26M
+15.2%
Renaissance Technologies
Filed 2025-11-13
$22M
-9.1%
Geode Capital Management
Filed 2025-11-12
$22M
-1.4%
2.44
Consensus
Sell—
—
—
9
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.